Provided by Tiger Trade Technology Pte. Ltd.

Quanex Building

17.71
+0.45002.61%
Post-market: 17.710.00000.00%16:20 EDT
Volume:403.34K
Turnover:7.13M
Market Cap:813.57M
PE:-3.38
High:17.95
Open:17.39
Low:16.92
Close:17.26
52wk High:22.98
52wk Low:11.04
Shares:45.94M
Float Shares:40.60M
Volume Ratio:0.45
T/O Rate:0.99%
Dividend:0.32
Dividend Rate:1.81%
EPS(TTM):-5.2423
EPS(LYR):-5.4322
ROE:-28.19%
ROA:3.91%
PB:1.11
PE(LYR):-3.26

Loading ...

BRIEF-Quanex Q4 Adjusted EPS USD 0.83 Vs. IBES Estimate USD 0.53

Reuters
·
Dec 12, 2025

Quanex Q4 Free Cash Flow USD 66.6 Million

THOMSON REUTERS
·
Dec 12, 2025

Quanex Q4 Adjusted EPS USD 0.83 VS. Ibes Estimate USD 0.53

THOMSON REUTERS
·
Dec 12, 2025

Quanex Building Products: "We Enter Fiscal 2026 With a Cautious Outlook Due to the Ongoing Macroeconomic Challenges"

THOMSON REUTERS
·
Dec 12, 2025

Quanex Q4 Gross Margin 28.1%

THOMSON REUTERS
·
Dec 12, 2025

Quanex Building Products Announces Fourth Quarter and Full Year 2025 Results

THOMSON REUTERS
·
Dec 12, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 11, 2025

NX Singapore Expands Its Tuas Global Logistics Centre on Singapore's Western Seafront

prnewswire
·
Dec 09, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 08, 2025

Nurix Therapeutics (NRIX): Valuation Check After New NX-5948 Phase 1a/1b Data at ASH 2025

Simply Wall St.
·
Dec 07, 2025

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire
·
Dec 06, 2025

Quanex Building Products Keeps Quarterly Dividend at $0.08 a Share, Payable Dec. 31 to Holders of Record Dec. 15

MT Newswires Live
·
Dec 06, 2025

Quanex Building Products declares $0.08 per share quarterly dividend

Reuters
·
Dec 06, 2025

NX Group Participates in Shanghai's 8th China International Import Expo (CIIE)

prnewswire
·
Dec 03, 2025

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire
·
Dec 01, 2025

NX China Receives China's Highest Rating of Class 5A Logistics Enterprise

prnewswire
·
Dec 01, 2025

Quanex Building Products Corporation to Announce Fourth Quarter and Full Year 2025 Results

Reuters
·
Nov 27, 2025

Nyse Order Imbalance 50516.0 Shares on Sell Side

THOMSON REUTERS
·
Nov 25, 2025

Nextracker (NXT) Unveils NX Earth Truss and MENA Venture Is Global Expansion Strategy Gaining Momentum?

Simply Wall St.
·
Nov 07, 2025

Quanex Building Products Files Initial Beneficial Ownership Statement for Director Mary Katherine Lawler

Reuters
·
Nov 04, 2025